68Ga DOTATATE PET/CT of Non–FDG-Avid Pulmonary Metastatic Hemangiopericytoma

Abstract

We present the FDG and Ga DOTATATE PET/CT findings of a 68-year-old woman with pulmonary metastases 28 years after her initial diagnosis of central nervous system hemangiopericytoma. The largest of the pulmonary lesions showed prominent Ga DOTATATE uptake with comparatively minimal FDG avidity. Hemangiopericytoma is a rare mesenchymal tumor that arises from malignant pericytes, cells that form the walls of capillaries and postcapillary venules. This case demonstrates the potential of radiolabeled somatostatin analogs as a therapeutic option in the setting of widespread metastatic disease.

Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis

“…Somatostatin receptor expression has been identified in pericytes from patients with interstitial lung disease 16 and retinal disease, 17 and avid 68 Ga-DOTATATE uptake has also been reported in a patient with a rare metastatic hemangiopericytoma. 18 Although endothelial cell SSTR2 expression has also been reported, 19 data from large publicly available RNAseq databases show very low or no SSTR2 expression in endothelial cells (eg, European Blueprint Study, 20 Tabula sapiens human cell atlas 21 ), which is consistent with our findings. SSTR2 expression in adipose tissue is corroborated by data from the Human Protein Atlas.…”

Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals

“…Furthermore, 68 Ga -Dodecane tetra-acetic acid tyrosine-3-octreotate ( 68 Ga-DOTATATE) is a PET radiopharmaceutical usually used for neuroendocrine-tumor imaging and now increasingly considered as an adjunctive imaging tracer for multiple solid neoplasms, including mesenchymal tumors [ 39 ]. Similarly to 111 In-Pentetreotide, 68 Ga-DOTATATE is a positron-emitter radiolabeled somatostatin analogue able to reveal a high concentration of surface SSRs, with the advantages of superior spatial resolution and accuracy, faster acquisition and lower radiation exposure [ 24 ]. In particular, Hung et al found negligible FDG uptake but intense 68 Ga-DOTATATE avidity of pulmonary metastases in a 68-year-old woman affected by primitive intracranial HPC [ 24 ].…”

“…Similarly to 111 In-Pentetreotide, 68 Ga-DOTATATE is a positron-emitter radiolabeled somatostatin analogue able to reveal a high concentration of surface SSRs, with the advantages of superior spatial resolution and accuracy, faster acquisition and lower radiation exposure [ 24 ]. In particular, Hung et al found negligible FDG uptake but intense 68 Ga-DOTATATE avidity of pulmonary metastases in a 68-year-old woman affected by primitive intracranial HPC [ 24 ].…”

Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68Ga]DOTATATE

“…Radiotherapy was performed with 59.4 Gy, which caused tumour regression and local control for several years. Eventually, the patient progressed and was evaluated for possible peptide receptor radionuclide therapy (PRRT) using [ 68 Ga]DOTATATE positron emission tomography/computed tomography (PET/CT), as previously it was described that hemangiopericytoma might show somatostatin receptor expression [ 1 ].…”